Function
Beta-ketoacyl carrier protein reductase (BKACPR) catalyzes the reaction of conversion of 3-hydroxyacyl-[acyl-carrier-protein] to 3-oxoacyl-[acyl-carrier-protein] while using NADPH as a reducing agent. BKACPR is part of the type II fatty acid biosynthesis pathway.
Relevance
BKACPR from Plasmodium falciparium inhibitors are tested as antimalarial drugs. Other BKACPR inhibitors are tested for combating toxoplasmosis and sleeping sickness.
Structural highlights
The active site interacting with co-factor NADPH contains the active site triad Ser, Tyr, Arg.